Jade Biosciences, Inc. (JBIO) Ownership
JBIO ownership summary
as of October 18, 2026- Institutions
- 116.2% of shares outstanding
- Insiders
- 0.79% of shares outstanding
- Shares outstanding
- 63.6M
- Float
- 52.0M shares available to trade
- Short interest
- 23.32% 12.1M shares short
- Days to cover
- 12.01 short interest up 10.3% vs prior month
- Institutions 116.17%
- Insiders 0.79%
JBIO top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | FMR Inc | 14.35% | 9.1M | $122.9M | +2.0M (+28.8%) | June 30, 2026 |
| 2 | Jupiter Topco LLC | 9.86% | 6.3M | $84.5M | +6.3M (0.0%) | June 30, 2026 |
| 3 | Fairmount Funds Management LLC | 7.16% | 4.6M | $61.3M | — | June 30, 2026 |
| 4 | RA Capital Management, LLC | 5.77% | 3.7M | $49.4M | — | June 30, 2026 |
| 5 | VR Adviser, LLC | 5.06% | 3.2M | $43.4M | — | June 30, 2026 |
| 6 | HHG PLC | 4.88% | 3.1M | $41.8M | +3.1M (0.0%) | March 31, 2026 |
| 7 | Bellevue Group AG | 4.81% | 3.1M | $41.2M | −443,506 (−12.7%) | June 30, 2026 |
| 8 | Paradigm Biocapital Advisors LP | 4.49% | 2.9M | $38.5M | +2.9M (0.0%) | June 30, 2026 |
| 9 | BlackRock Inc | 4.41% | 2.8M | $37.7M | +487,502 (+21.1%) | June 30, 2026 |
| 10 | Franklin Templeton Inc | 4.39% | 2.8M | $37.6M | +2.8M (0.0%) | June 30, 2026 |
| 11 | State Street Corp | 3.67% | 2.3M | $31.5M | +1.7M (+256.2%) | June 30, 2026 |
| 12 | Vanguard Capital Management, LLC | 3.53% | 2.2M | $30.2M | +448,121 (+24.9%) | June 30, 2026 |
| 13 | Adage Capital Partners Gp LLC | 3.00% | 1.9M | $25.7M | +1.9M (0.0%) | June 30, 2026 |
| 14 | Polar Capital Holdings PLC | 2.90% | 1.8M | $24.9M | +1.8M (0.0%) | June 30, 2026 |
| 15 | Avidity Partners Management LP | 2.67% | 1.7M | $22.9M | −1.1M (−39.3%) | June 30, 2026 |
| 16 | Remedium Capital Partners, LLC | 2.48% | 1.6M | $21.3M | — | June 30, 2026 |
| 17 | Soleus Capital Management, L.P. | 2.44% | 1.6M | $20.9M | +753,946 (+94.6%) | June 30, 2026 |
| 18 | JPMorgan Chase & Co | 2.32% | 1.5M | $19.9M | +1.5M (+9,198.9%) | June 30, 2026 |
| 19 | Baker Bros Advisors LP | 1.93% | 1.2M | $16.6M | −410,711 (−25.0%) | June 30, 2026 |
| 20 | Logos Global Management LP | 1.77% | 1.1M | $15.2M | +725,000 (+181.2%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 13 holders added 26.4M shares and 3 cut 2.0M.
JBIO top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Polar Capital Biotech S Inc | 2.75% | 1.7M | $23.6M | — | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 2.71% | 1.7M | $23.2M | −33,000 (−1.9%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 2.67% | 1.7M | $22.9M | — | August 31, 2026 |
| 4 | Franklin Small Cap Value A | 2.56% | 1.6M | $21.9M | +215,984 (+15.3%) | August 31, 2026 |
| 5 | Fidelity Growth Company Fund | 1.87% | 1.2M | $16.1M | — | August 31, 2026 |
| 6 | iShares Russell 2000 ETF | 1.62% | 1.0M | $13.9M | −11,904 (−1.1%) | September 30, 2026 |
| 7 | Fidelity Select Health Care | 1.57% | 1.0M | $13.5M | +180,422 (+22.0%) | August 31, 2026 |
| 8 | Janus Henderson Global Life Sciences D | 1.55% | 988K | $13.3M | +90,426 (+10.1%) | August 31, 2026 |
| 9 | Janus Henderson Hrzn Biotec E2 USD | 1.51% | 963K | $13.0M | +215,855 (+28.9%) | June 30, 2026 |
| 10 | Janus Henderson Glb Life Scn I2 USD | 1.49% | 946K | $12.7M | +247,745 (+35.5%) | August 31, 2026 |
| 11 | Fidelity Stock Selector Small Cap | 1.43% | 908K | $12.2M | — | July 31, 2026 |
| 12 | Franklin Biotechnology Discv A(acc)USD | 1.40% | 888K | $12.0M | — | August 31, 2026 |
| 13 | Fidelity Small Cap Growth | 1.23% | 780K | $10.5M | — | July 31, 2026 |
| 14 | Fidelity Advisor Biotechnology I | 1.17% | 742K | $10.0M | +42,972 (+6.2%) | August 31, 2026 |
| 15 | Janus Global Life Science AUSD | 1.10% | 698K | $9.4M | +697,886 (0.0%) | June 30, 2026 |
| 16 | JPMorgan Small Cap Growth A | 1.02% | 649K | $8.7M | −19,150 (−2.9%) | August 31, 2026 |
| 17 | Fidelity Series Small Cap Opps | 0.93% | 589K | $7.9M | — | July 31, 2026 |
| 18 | Franklin Small Cap Value VIP 1 | 0.79% | 503K | $6.8M | +69,325 (+16.0%) | August 31, 2026 |
| 19 | Fidelity Advisor Health Care I | 0.79% | 500K | $6.7M | +129,400 (+34.9%) | August 31, 2026 |
| 20 | Pictet-Biotech P USD | 0.76% | 483K | $6.5M | +215,164 (+80.3%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
JBIO shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns JBIO
Institutional investors own 116.2% of Jade Biosciences's shares and insiders 0.79%. The largest holder is FMR Inc with 14.35% of the shares (9.1M), as of June 30, 2026. Among the top 20 institutions, 13 added shares and 3 reduced their stake in the latest filings. Short interest is 23.32% of the float, or 12.01 days of average trading volume. The share count rose 4,831.6% since 2021.
Related: JBIO analyst forecast, JBIO key metrics. See the JBIO stock overview for the latest quote and news.
JBIO ownership FAQ
Who owns the most Jade Biosciences stock?
The largest shareholders of Jade Biosciences are FMR Inc (14.35%), Jupiter Topco LLC (9.86%), Fairmount Funds Management LLC (7.16%), RA Capital Management, LLC (5.77%), VR Adviser, LLC (5.06%).
What percentage of Jade Biosciences is owned by institutions?
Institutions hold 116.2% of Jade Biosciences's shares outstanding; insiders hold 0.79%.
Which funds own Jade Biosciences?
The largest fund holders of Jade Biosciences are Polar Capital Biotech S Inc (2.75%), State Street® SPDR® S&P® Biotech ETF (2.71%), Vanguard MStar Total Stk Mkt Idx Invest (2.67%), Franklin Small Cap Value A (2.56%), Fidelity Growth Company Fund (1.87%).
What is Jade Biosciences's short interest?
12.1M shares of Jade Biosciences were sold short, 23.32% of the float; at the average daily volume it would take 12.01 days to cover.
How many shares of Jade Biosciences are outstanding?
Jade Biosciences has 63.6M shares outstanding, of which 52.0M are in the public float.